International Assets Investment Management LLC Boosts Stake in UiPath Inc. (NYSE:PATH)

International Assets Investment Management LLC increased its position in shares of UiPath Inc. (NYSE:PATH) by 1,649.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 177,358 shares of the healthcare company’s stock after acquiring an additional 167,218 shares during the quarter. International Assets Investment Management LLC’s holdings in UiPath were worth $4,406,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in PATH. Royal London Asset Management Ltd. boosted its position in UiPath by 5.9% in the 3rd quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock valued at $2,388,000 after buying an additional 7,742 shares during the period. O Shaughnessy Asset Management LLC purchased a new stake in UiPath during the 3rd quarter worth about $203,000. Invesco Ltd. raised its position in UiPath by 2.8% in the 3rd quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock valued at $6,830,000 after purchasing an additional 10,863 shares in the last quarter. Symmetry Partners LLC purchased a new position in shares of UiPath in the 4th quarter valued at about $205,000. Finally, Toroso Investments LLC grew its position in shares of UiPath by 196.7% during the third quarter. Toroso Investments LLC now owns 78,189 shares of the healthcare company’s stock worth $1,338,000 after buying an additional 51,834 shares in the last quarter. Hedge funds and other institutional investors own 62.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Evercore ISI increased their price objective on shares of UiPath from $24.00 to $27.00 and gave the company an “in-line” rating in a research report on Thursday, March 14th. Truist Financial restated a “buy” rating and set a $32.00 target price on shares of UiPath in a research note on Wednesday, March 20th. Morgan Stanley raised their price objective on shares of UiPath from $17.00 to $25.00 and gave the stock an “equal weight” rating in a report on Thursday, March 14th. JPMorgan Chase & Co. upgraded shares of UiPath from a “neutral” rating to an “overweight” rating and upped their target price for the company from $22.00 to $28.00 in a report on Thursday, March 14th. Finally, KeyCorp began coverage on UiPath in a research report on Monday, April 8th. They set an “overweight” rating and a $27.00 target price on the stock. Nine analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $27.41.

Insider Buying and Selling at UiPath

In other news, CFO Ashim Gupta sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $19.79, for a total transaction of $791,600.00. Following the sale, the chief financial officer now owns 946,848 shares of the company’s stock, valued at approximately $18,738,121.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders sold 96,000 shares of company stock valued at $2,023,440. Corporate insiders own 31.03% of the company’s stock.

UiPath Trading Down 0.6 %

Shares of PATH opened at $19.89 on Thursday. UiPath Inc. has a twelve month low of $13.30 and a twelve month high of $27.87. The firm has a market capitalization of $11.32 billion, a PE ratio of -117.06 and a beta of 1.01. The stock’s 50 day moving average is $21.60 and its two-hundred day moving average is $21.78.

UiPath (NYSE:PATH) last issued its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.10. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. The company had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. On average, sell-side analysts predict that UiPath Inc. will post -0.04 EPS for the current year.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.